Meeting
2017 ASCO Annual Meeting
Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.
Authors
Julia Foldi
Yale Cancer Center, New Haven, CT
Julia Foldi , Sarah Schellhorn Mougalian , Andrea Silber , Donald R. Lannin , Brigid K. Killelea , Anees B. Chagpar , Nina Ruth Horowitz , Courtney Frederick , Lawrence Rispoli , Maysa M. Abu-Khalaf , Kert D. Sabbath , Tara Beth Sanft , Neal A. Fischbach , Debra S. Brandt , Erin Wysong Hofstatter , Michael DiGiovanna , Lajos Pusztai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT01855828
Citation
J Clin Oncol 35, 2017 (suppl; abstr 577)
DOI
10.1200/JCO.2017.35.15_suppl.577
Abstract #
577
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring
Poster
2012 ASCO Annual Meeting
Estrogen receptor (ER), Ki-67, p27Kip1, and histologic grade as predictors of pathologic complete response (pCR) in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy (NAC) using fluorouracil, epirubicin, and cyclophosphamide (FEC), taxanes, and trastuzumab.
First Author: Sasagu Kurozumi
Poster
2016 ASCO Annual Meeting
Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).
First Author: Sherko Kümmel
Poster
2015 ASCO Annual Meeting
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.
First Author: Naoko Matsuda